Compounds > atorvastatin
Page last updated: 2024-08-24

atorvastatin and saquinavir

atorvastatin has been researched along with saquinavir in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (18.18)18.2507
2000's3 (27.27)29.6817
2010's5 (45.45)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Andricopulo, AD; Moda, TL; Montanari, CA1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Houston, JB; Jigorel, E1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Egbert, M; Keserű, GM; Vajda, S; Whitty, A1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Henry, K; Hermundson, J; Huebesch, J; Melroe, H; Simpson, J1
Martín, T; Murillas, J; Portero, JL; Ramos, A1
Aberg, JA; Alston, B; Aweeka, F; Blaschke, T; Fang, F; Fichtenbaum, CJ; Gerber, JG; Kosel, B; Rosenkranz, SL; Segal, Y1

Reviews

2 review(s) available for atorvastatin and saquinavir

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022

Trials

1 trial(s) available for atorvastatin and saquinavir

ArticleYear
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
    AIDS (London, England), 2002, Mar-08, Volume: 16, Issue:4

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; HIV Seronegativity; Human Experimentation; Humans; Pravastatin; Pyrroles; Ritonavir; Saquinavir; Simvastatin

2002

Other Studies

8 other study(ies) available for atorvastatin and saquinavir

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:8

    Topics: Animals; Hepatocytes; Male; Pharmacokinetics; Rats; Rats, Sprague-Dawley

2012
Why Some Targets Benefit from beyond Rule of Five Drugs.
    Journal of medicinal chemistry, 2019, 11-27, Volume: 62, Issue:22

    Topics: Binding Sites; Drug Discovery; Ligands; Molecular Weight; Protein Binding

2019
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
    Lancet (London, England), 1998, Sep-26, Volume: 352, Issue:9133

    Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Protease Inhibitors; Pyrroles; Ritonavir; Saquinavir

1998
Atorvastatin for protease inhibitor-related hyperlipidaemia.
    AIDS (London, England), 1999, Jul-30, Volume: 13, Issue:11

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Male; Pyrroles; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir

1999